Table IV.

Multivariate analysis of DFS-associated prognostic factors among NSCLC patients (n=35) with p-stage IIIA disease who underwent adjuvant chemotherapy.

Variable	Comparison	Odds ratio	95% confidence interval	P-value
EGFR status	Wild-type vs. mutant	0.337	0.139–0.818	0.016
Regimen (CD-DST)	Non-sensitive vs. sensitive	3.152	1.315–7.554	0.010

HSCLC, non-small cell lung cancer; DFS, disease-free survival; EGFR, epidermal growth factor receptor; CD-DST, collagen gel droplet embedded culture drug sensitivity test.